Grzegorz (greg) Nowakowski MD

Grzegorz (Greg) S. Nowakowski, M.D., is a consultant and a Professor of Oncology and Medicine, Division of Hematology. He also serves as the Deputy Director of Mayo Clinic Comprehensive Cancer Center for Clinical Research and the Vice-Chair of the Division of Hematology.

Dr. Nowakowski is an internationally recognized researcher and leader. His research focuses on the molecular classification and biology of lymphoproliferative disorders, new approaches to clinical trial design, and novel therapies for lymphoma and hematological disorders. He is a principal investigator for multiple investigator-initiated and cooperative-group clinical trials (ECOG, Alliance) and industry-sponsored and investigator-initiated studies. He is a member of the ECOG Lymphoma Core Committee, chair of the American Society of Hematology (ASH) Clinical Trial Innovation Subcommittee, co-chair of the ASH-FDA Regulatory Science Workshop, and chair of the American Society of Clinical Oncology (ASCO) Clinical Trial Access and Participation Taskforce.

Dr. Nowakowski has significant regulatory experience. He has served as principal investigator of regulatory studies and worked with regulatory agencies, including serving as a voting member of the Oncology Drugs Advisory Committee (ODAC) to the Food and Drug Administration (FDA). He has authored over 250 articles and numerous book chapters and mentored many faculty members in the U.S. and abroad.